| NMR | Nuclear Magnetic Resonance; 핵자기 공명술 |
|---|---|
| PMN | Poly-Morpho-Nuclear Leukocytes |
| PMNL | Poly-Morpho-Nuclear neutrophilic Leukocyte |
| ACNM | American College of Nuclear Medicine; American College of Nurse-Midwives |
| ACNP | acute care nurse practitioner; American College of Nuclear Physicians |
| complete antigen | Any antigen capable of stimulating the formation of antibody with which it reacts in vivo or in vitro, as distinguished from incomplete antigen (hapten). (05 Mar 2000) |
|---|---|
| conjugated antigen | A hapten that may cause the production of antibodies when it has been covalently linked to protein. Synonym: conjugated antigen. (05 Mar 2000) |
| mumps skin test antigen | A sterile suspension of killed mumps virus in isotonic sodium chloride solution, used to determine susceptibility to mumps or to confirm previous exposure. (05 Mar 2000) |
| pollen antigen | An extract of the antigenic protein from the pollen of plants; i.e., pollen allergen, used in the diagnosis and prevention of hay fever. (05 Mar 2000) |
| H-2 antigen | <immunology> Antigen coded in the major group of transplantation antigens in the mouse. See: H-2 complex, histocompatability antigen. (20 Jun 2000) |
| h antigen | <microbiology> Any bacteria which has a long flagella that is used for movement. The term is used by immunologists and serologists as a form of classification. (09 Oct 1997) |
| cystic fibrosis antigen | Now known to be MRP 8. See: calgranulins. (18 Nov 1997) |
| heart antigen | A diphosphatidyl glycerol that is found in the membrane of Treponema pallidum and is the antigen detected by the Wasserman test for syphilis. (18 Nov 1997) |
| S antigen | Viral antigen that remains in solution after the particles of virus have been removed by means of centrifugation; in the case of the influenza viruses, it is the internal helical structure, free of the external envelope. Synonym: S antigen. (05 Mar 2000) |
| hepatitis-associated antigen | A term used for the surface antigen of hepatitis B virus before its nature was established. See: hepatitis B surface antigen. (05 Mar 2000) |
| hepatitis B antigen | Antigens of the virion of the hepatitis b virus or the dane particle, its surface, core and other associated antigens, like the hbe antigen. (12 Dec 1998) |
| hepatitis B core antigen | <virology> (HBcAb, HBcAg), the antigen found in the core of the Dane particle (which is the complete virus) and also in hepatocyte nuclei in hepatitis B infections. (05 Mar 2000) |
| hepatitis B e antigen | (HBeAb, HBe, HBeAg), an antigen, or group of antigen's, associated with hepatitis B infection and distinct from the surface antigen (HBsAg) and the core antigen (HBcAg); it is associated with the viral nucleocapsid. Its presence indicates that the virus is replicating and the individual is potentially infectious. (05 Mar 2000) |
| hepatitis B surface antigen | <virology> A serologic marker on the surface of the hepatitis B virus. The body will normally produce antibodies to hepatitis B surface antigen as part of the normal immune response to infection. It is the presence of antibodies to the hepatitis B surface antigen that are detected in a positive hepatitis B blood test. (27 Sep 1997) |
| prostate-specific antigen | <tumour marker> A simple blood test used to detect prostate cancer in men. The test measures a specific antigen normally secreted by the prostate. If cancer is developing, the prostate secretes greater amounts of prostate-specific antigen. This test is recommended for men with an enlarged prostate and an increased risk of prostate cancer. It is an enzyme that is produced by epithelial cells of both benign and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer. It is a single chain 31 kilodalton glycoprotein with 240 amino acid residues and 4 carbohydrate side chains that is a kallikrein protease. It is found in normal seminal fluid and produced by the prostatic epithelial cells. Elevated levels in blood serum are associated with prostatic enlargement and prostatic adenocarcinoma, and this allows early detection of cancer in many cases. In about 70% of cases, the rise is due to a cancerous condition. No large scale clinical studies have been completed to assess the impact of testing on survival from prostate cancer, and the medical and economic value of testing remain uncertain. Acronym: PSA Registry number: EC 3.4.21.77 (22 Sep 2002) |